AstraZeneca PLC (AZN)
| Market Cap | 244.84B +6.8% |
| Revenue (ttm) | 61.37B +8.6% |
| Net Income | 10.45B +25.9% |
| EPS | 6.68 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 23.44 |
| Forward PE | 14.57 |
| Dividend | $3.23 (2.08%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 8,093,360 |
| Open | 157.95 |
| Previous Close | 157.97 |
| Day's Range | 155.32 - 158.56 |
| 52-Week Range | 141.77 - 212.71 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 213.69 (+37.32%) |
| Earnings Date | Jul 27, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is $213.69, which is an increase of 37.32% from the latest price.
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN). Such investors are advised to...
AstraZeneca deal talks with Bristol Myers remain active, Semafor says
AstraZeneca’s (AZN) merger talks with Bristol Myers (BMY) remain active, Liz Hoffman of Semafor reports. A potential deal would move AstraZeneca’s revenues further away from the UK and Europe and…
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) s...
More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Is AstraZeneca PLC (AZN) a Bargain After 6.9% Drop? GF Value Says Undervalued
Is AstraZeneca PLC (AZN) a Bargain After 6.9% Drop? GF Value Says Undervalued
Goldman Sachs's Hader on why AstraZeneca's stock fell on news of possible merger with Bristol Myers
Asad Haider, Goldman Sachs Healthcare Analyst, joins 'Closing Bell Overtime' to talk a possible merger between Bristol Myers and AstraZeneca.
Soriot plots pharma Brexit: Labour's failures have alienated a national champion, says ALEX BRUMMER
Pascal Soriot, pictured, has been on a glorious path as AstraZeneca boss, cataputing the medicines giant to number two in the FTSE 100.
AZN Looks 12.5% Undervalued on GF Value⢠as Dividend Remains Secure
AZN Looks 12.5% Undervalued on GF Value⢠as Dividend Remains Secure
European Stocks Rise as Oil Prices Fall Amid US-Iran Tensions, AstraZeneca Drops
European Stocks Rise as Oil Prices Fall Amid US-Iran Tensions, AstraZeneca Drops
TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger
TD Cowen analyst Steve Scala doesn’t see logic in combination of AstraZeneca (AZN) and Bristol Myers (BMY). If combined, AstraZeneca’s 2027-2032 sales growth would be diluted by two percentage points,...
FTSE 100 Slips as AstraZeneca Falls on Merger Reports
London shares edged lower as AstraZeneca losses outweighed gains from housebuilders and shipping stocks. The post FTSE 100 Slips as AstraZeneca Falls on Merger Reports appeared first on Investomania .
AstraZeneca Shares Slide on $400bn Bristol Myers Merger Talks
AstraZeneca falls as investors question the value, risks and strategic logic behind a potential Bristol Myers deal. The post AstraZeneca Shares Slide on $400bn Bristol Myers Merger Talks appeared firs...
AZN Looks 14.0% Undervalued on GF Value⢠Amid Dividend Sustainability Concerns
AZN Looks 14.0% Undervalued on GF Value⢠Amid Dividend Sustainability Concerns
AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks
AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks
AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger
The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling • AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm Sir Pascal Soriot, ...
AstraZeneca–Bristol Myers Squibb merger 'is not highly likely to happen,' says UBS' Michael Yee
Michael Yee, UBS global head of biotech research, joins 'Squawk on the Street' to discuss the potential mega-merger between UK pharmaceutical company AstraZeneca and its U.S. competitor Bristol Myers ...
Stocks mixed as AstraZeneca merger talk dents FTSE 100
The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
AstraZeneca (AZN) Faces Significant Drop, Hits Lowest Level Since 2025
AstraZeneca (AZN) Faces Significant Drop, Hits Lowest Level Since 2025
Astra Buying Bristol Makes No Sense, Fazeli Says
AstraZeneca shares plunged Monday on news that the drugmaker was exploring an acquisition of Bristol Meyers Squibb. A deal would create one of the world's biggest drugmakers.
Bristol-Myers stock: why AstraZeneca merger is unlikely to happen
Bristol-Myers Squibb (BMY) stock is declining this morning, reversing its premarket gains as Wall Street digests bombshell reports of a potential transatlantic merger with AstraZeneca (AZN). According...
AZN Looks 5.6% Undervalued on GF Valueâ¢
AZN Looks 5.6% Undervalued on GF Valueâ¢
Potential Merger Between Bristol-Myers Squibb (BMY) and AstraZeneca Raises Concerns
Potential Merger Between Bristol-Myers Squibb (BMY) and AstraZeneca Raises Concerns
AZN Looks 5.6% Undervalued on GF Value⢠Amid Strong Dividend Fundamentals
AZN Looks 5.6% Undervalued on GF Value⢠Amid Strong Dividend Fundamentals
Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.
AstraZeneca (AZN) and Bristol Myers Squibb (BMY) Explore Potential Merger
AstraZeneca (AZN) and Bristol Myers Squibb (BMY) Explore Potential Merger